Skip to main content
Erschienen in: Reactions Weekly 1/2021

01.09.2021 | Case report

Epidermal-growth-factor-receptor-antagonists

Paronychia with pseudopyogenic granulomas: 10 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Olamiju B, et al. Management of paronychia with pseudopyogenic granulomas secondary to epidermal growth factor receptor inhibitors: An assessment of topical timolol and the need for multiple medical and procedural therapies. Journal of the American Academy of Dermatology 84: 806-808, No. 3, Mar 2021. Available from: URL: http://doi.org/10.1016/j.jaad.2020.06.010CrossRef Olamiju B, et al. Management of paronychia with pseudopyogenic granulomas secondary to epidermal growth factor receptor inhibitors: An assessment of topical timolol and the need for multiple medical and procedural therapies. Journal of the American Academy of Dermatology 84: 806-808, No. 3, Mar 2021. Available from: URL: http://​doi.​org/​10.​1016/​j.​jaad.​2020.​06.​010CrossRef
Metadaten
Titel
Epidermal-growth-factor-receptor-antagonists
Paronychia with pseudopyogenic granulomas: 10 case reports
Publikationsdatum
01.09.2021
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-021-02125-z

Weitere Artikel der Ausgabe 1/2021

Reactions Weekly 1/2021 Zur Ausgabe

Case report

Doxorubicin